Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study (Q80270247)

From Wikidata

Jump to navigation Jump to search

scientific article published on 03 May 2007

Language	Label	Description	Also known as
English	Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study	scientific article published on 03 May 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

Laura J. Havrilesky

5

object named as

Laura J Havrilesky

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Angeles Alvarez Secord

1

object named as

Angeles Alvarez Secord

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Kathleen M Darcy

2

object named as

Kathleen M Darcy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Andrew Berchuck

7

object named as

Andrew Berchuck

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

6

object named as

Lisa A Grace

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

3

object named as

Alan Hutson

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Paula S Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Gynecologic Oncology Group study

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

3 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

106

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

221-232

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Clinical applications of angiogenic growth factors and their inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Antiangiogenic agents and their promising potential in combined therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-1 and cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Expression of Thrombospondin-1 in Resected Colorectal Liver Metastases Predicts Poor Prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin-induced attachment and spreading of human squamous carcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Thrombospondin modulates alpha v beta 3 function through integrin-associated protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Ovarian cancer p53 mutation is associated with tumor microvessel density

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.03.021

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.03.021

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17481705%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80270247&oldid=2227712879"